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a  b  s  t  r  a  c  t
Thrombocytopenia  is  common  in  patients  with  myelodysplastic  syndromes  (MDS)  and  immune
destruction  of  platelets  could  be  an  important  factor  for  its  occurrence.  We  prospectively  analyzed
platelet-associated  IgG  (PAIgG)  through  platelet  immunoﬂuorescence  test  (PIFT),  mean  platelet  vol-
ume (MPV),  platelet  size  deviation  width  (PDW)  and  glycocalicin  index  (GCI)  of  54 patients  with
MDS,  classiﬁed  according  to  the  International  Prognostic  Scoring  System  (IPSS).  Thrombocytopeniaeywords:
yelodysplastic syndrome
hrombocytopenia
IFT
latelet indices
(platelet  count  < 100  × 109/L)  was  correlated  with  a higher  amount  of  PAIgG,  signiﬁcantly  higher  MPV
and  increased  GCI.  In  addition,  worse  prognosis  IPSS  groups  were  associated  with  a  higher  positivity  of
PIFT, which  could  be  indicative  of  advanced  disease.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license. lycocalicin index
. Introduction
Myelodysplastic syndromes (MDSs) are a group of hematopoi-
tic stem cell disorders characterized by ineffective hematopoeisis
nd an increased risk of transformation into acute myelogenous
eukemia (AML) [1].  Thrombocytopenia is identiﬁable in up to
wo thirds of patients with MDS  and severe thrombocytopenia is
resent in approximately 10%. The cause of the altered megakary-
cytopoiesis in MDS  has not yet been elucidated, however studies
ndicate that an increased apoptosis of early progenitors, inhibitory
ffects of cytokines [2–6], bone marrow ﬁbrosis [7] and immune-
ediated mechanisms [5,8,9] might contribute to this process.
everal clinical and immunological studies suggest a signiﬁcant
eregulation of the immune system in the complex pathogene-
is of MDS. This deregulation may  even promote the progression
f early MDS  towards advanced MDS. Although immunological
bnormalities are frequent in MDS  patients, the speciﬁc and clinical
onsequences of these phenomena remain unclear.
Immune thrombocytopenia (ITP) is an autoimmune disease
ffecting adults and children, in which most patients have
∗ Corresponding author at: Hematology and Hemotherapy Center, University of
ampinas. Address: Rua Carlos Chagas, 480. Cidade Universitária “Zeferino Vaz”,
ampinas-SP, CEP 13083-970 Brazil. Tel.: +55 19 35218734; fax: +55 19 32891089.
E-mail address: mona@unicamp.br (S.C.O. Gilli).
145-2126 ©  2011 Elsevier Ltd. 
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Open access under the Elsevier OA license. autoantibodies that accelerate platelet destruction and may also
impair megakaryocyte platelet production. Platelet autoantibod-
ies may  be sensitively determined directly on the platelet surface
in patients with autoimmune-mediated thrombocytopenia [10].
The assays for the detection of glycoprotein-speciﬁc antibodies
such as monoclonal antibody-speciﬁc immobilization of platelet
antigens (MAIPA) are highly speciﬁc but less sensitive [11], they
are laborious and require a higher amount of platelets than other
assays for the detection of platelet-associated IgG, such as platelet
immunoﬂuorescence test (PIFT). Platelet immunoﬂuorescence test
[12] has been widely used for detection of platelet associated IgG
(PAIgG) on the platelet surface (direct PIFT).
Additionally, it has been demonstrated that some morphological
platelet indices correlate with the occurrence of immune thrombo-
cytopenia and could be of value in discriminating hyperdestructive
from hypoproductive thrombocytopenia, however little attention
has been paid to platelet size in one same measurement. Mea-
sures of platelet size, such as mean platelet volume (MPV) [13,14],
platelet size deviation width (PDW) and platelet large cell ratio (P-
LCR) [15] have been known to aid in the differential diagnosis of
thrombocytopenia.
Three laboratory methods have been reported to be useful
for the diagnosis of thrombocytopenia. These include reticulated
platelets (RPs), plasma thrombopoietin (TPO) levels, and plasma
glycocalicin (GC) levels. GC is a carbohydrate-rich hydrophilic
fragment. Its levels are signiﬁcantly reduced in patients with
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Table 1
Clinical and laboratory characteristic of the studies patients according to IPSS classiﬁcation.
Platelet counts lower than 100 × 109/L Platelet count 100 × 109/Lor more
No. patients 24 30
Low  IPSS 6 20
INT-1 14 9
INT-2  2 –
High  IPSS 1 –
No.  male/female 14/10 14/16
Age,  y, median 62.7 73.0
Hb,  g/dL. median 9.8 10.5
ANC,  ×109/L, median (range) 1435 (480–4660) 1765(310–8410)
MPV  median (range) 9.9(6.9–23.1) 8.3(4.8–12.8)
PDW,  median (range) 15.3(10.1–21.9) 16.3(14.1–23.5)
GC  index (range) 3.8(1.4–26.2) 1.1 (0.3–2.8)
R  direct PIFT-FC test, median (range) 2.1 (0.4–27.8) 1.1 (0.5–4.2)
IPSS indicates International Prognostic Scoring System. Low: low risk, INT: intermediary risk, High: high risk, ANC: absolute neutrophils count, MPV: mean platelet volume,
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rDW:  platelet size deviation, GC index: glycocalicin index, R: ratio between patient i
nd  classiﬁcation of MDS  were based on hematological, pathological and chromosom
Abbott, Illinois, USA).
ypoplastic thrombocytopenia, but not in patients with normal
r increased megakaryocytes [16] suggesting that plasma GC level
eﬂects the rate of platelet production. In addition, the GC index
plasma GC level normalized for the individual platelet count) is
levated in patients with ITP but not in patients with AA, suggest-
ng that the GC index reﬂects the rate of platelet destruction. Plasma
evels of GC could be of relevance to discriminate further between
n increased destruction of platelets in peripheral blood and an
mpaired production by the bone marrow megakaryocytes.
Since it is imperative to know whether thrombocytopenia in
DS  is mainly due to hypo-production or hyper-destruction of
latelets, as this could possibly imply in important changes in
atient care, the aim of the present study was to evaluate prospec-
ively the prevalence of platelet antibodies, and determine the
sefulness of quantitative PAIgG detection for the differential diag-
osis of thrombocytopenia in MDS  patients by a combination of
his highly sensitive direct ﬂow cytometric analysis and the glyco-
alicin index, and to assess the convenience of applying PDW and
PV measures as indirect markers of hyperdestruction of platelets
n MDS.
. Materials and methods
.1. Patients and platelet indices acquisition
A  total of ﬁfty-four consecutive patients with a diagnosis of MDS  from the
ematology and Hemotherapy Center of the University of Campinas (Hemocentro-
NICAMP) were enrolled in the study and were fully evaluated after written
nformed consent. The study was approved by the Ethical Committee of UNICAMP.
he patients were not subjected to steroids, immunosuppressive therapy or prior
latelet transfusions. The diagnosis and classiﬁcation of MDS  were based on hema-
ological, pathological and chromosomal analysis. Patients were grouped according
o the International Prognostic Scoring System – IPSS [17] which is used to deﬁne
DS  prognosis. The patients were screened for autoimmune disease and had no
linical or laboratory manifestation of immunological disorder at the time of being
nrolled in the study. All blood samples were prepared and analyzed on the day
f  collection. Cell-dyn Sapphire blood cell analyzer (Abbott, Illinois, USA) was  used
o  measure platelet counts, mean platelet volume (MPV) and platelet size devia-
ion  width (PDW). The referential ranges at our institute were 6.9–10.6 fL for MPV
nd 7.0–11.0 fL for PDW. Thrombocytopenia was  deﬁned as a platelet count below
00  × 109/L.
.2. Direct platelet immunoﬂuorescence test (PIFT-FC)
For the determination of platelet associated IgG (PAIgG) blood samples were
nalyzed by direct PIFT (platelet immunoﬂuorescence test) and results were
xpressed as a ratio R (patient immunoﬂuorescence/positive control immunoﬂu-
rescence). Brieﬂy, 5 × 106 platelets from patients were incubated with ﬂuorescein
FITC)-conjugated Polyclonal afﬁnity isolated F(ab′)2 Fragment Rabbit Anti-Human
gG,  (DakoCytomationTM – Glostrup – Denmark) diluted 1:20 for 30 min  at room
emperature in the dark. This sample was  then washed with PBS/EDTA 1% and
essuspended in 500 L buffer. Reading – 10,000 events – was performed in anoﬂuorescence direct PIFT test/positive control immunoﬂuorescence. The diagnosis
lysis and the blood samples were analyzed by Cell-dyn Sapphire blood cell analyzer
FACScalibur (Becton-Dickenson, San Jose, California) ﬂow cytometer. A positive test
was  deﬁned by ﬂuorescence ≥2 standard deviation – sd – from negative control and
inconclusive test by ﬂuorescence ≥1 sd, < 2 sd from negative control.
2.3. Plasma glycocalicin assay
Plasma glycocalicin (GC) was measured by commercially available enzyme
immunoassay (EIA) (Takara Shuzo, Ohtsu, Japan). Brieﬂy, 200 L of the sam-
ples of rich platelet plasma (RPP) were added to a microtiter plate precoated
with  anti-GC monoclonal antibody. After washing, anti-GC antibody was added
and  the GC concentration from the patients’ samples was calculated from the
corresponding standard curve. Since GC levels are dependent on the platelet
count, the GC index (GCI) was calculated using the following formula: GC
(g/mL) × 250 × 103/individual platelet count (/L), as proposed by Steinberg et al.
[16].  According to the literature, we considered 0.7 ± 0.2 as the normal value of GCI
[18].
2.4.  Statistical analysis
Statistical analysis was performed to compare platelet count with MPV,
PDW, glycocalicin index, and direct PIFT. Statistical analysis was  performed using
Kruskal–Wallis nonparametric analysis of variances and the Wilcoxon 2 sample test.
Spearman rank correlation was used for assessing correlations between continuous
variables. P < 0.05 was  considered statistically signiﬁcant.
3. Results
3.1. Prevalence of thrombocytopenia in MDS patients
According to the IPSS classiﬁcation, there were 26 cases
classiﬁed as low-risk, 23 cases intermediate-1 risk, 3 cases
intermediate-2 risk and 1 case was classiﬁed as high-risk; one
patient was not classiﬁed. The median platelet count in the sam-
ples was 120.5 × 109/L (ranging from 6.7 to 708.0 × 109/L), mean
153.3 ± 131.4 × 109/L. Twenty four patients (44.4%) had platelet
counts <100 × 109/L. Data of patients are summarized in Table 1.
3.2. MPV was signiﬁcantly higher in patients with
thrombocytopenia
MPV  was signiﬁcantly higher in patients with platelet
count <100 × 109/L (median, min–max: 9.93, 6.9–23.1 vs 8.32,
4.88–12.83; p < 0.001, Wilcoxon rank sum test with continuity
correction), and platelet count was signiﬁcantly different among
patients with MPV  below the lower limit of normal, within the
normal range of MPV, and with MPV  above the upper limit of nor-
mal  (median, min–max: 183.5 × 109/L, 135.0–261.0; 120.5 × 109/L,
20.3–708.0; 28.5 × 109/L, 6.7–267.0; p = 0.01, Kruskal–Wallis rank
sum test). In addition, an inverse correlation between the num-
ber of platelets and the MPV  value was demonstrated (p < 0.001,
r = −0.45, Spearman’s rank correlation rho) (Fig. 1). Taken together,
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dig. 1. Association between MPV  indices and platelet count. MPV  is signiﬁcantly
orrelation between platelet count and MVP  indices (B).
hese results show that thrombocytopenia in MDS  is associated
ith an elevated MPV. With reference to PDW, there was no statis-
ical difference between these groups.
.3. Association between thrombocytopenia and the amount of
AIgG measured by direct platelet immunoﬂuorescence test (R)
Direct PIFT (platelet immunoﬂuorescence test) was  positive in
8 patients, negative in 20 and inconclusive in 6. An association
as demonstrated between thrombocytopenia and the amount of
AIgG measured by PIFT, taking the following three analysis into
ccount: an inverse correlation between the number of platelets
nd the ﬂuorescence ratio (p = 0.01, r = −0.31, Spearman’s rank cor-
elation rho), the higher positivity of PIFT in patients with platelet
ount <100 ×109/L (median, min–max: 2.17, 0.47–27.88 vs 1.13,
.58–4.22; p = 0.004, Wilcoxon rank sum test with continuity cor-
ection), and a lower platelet count in patients with positive PIFT,
ompared to negative results (median, min–max: 87.1, 6.7–380.0
s 150.0, 9.1–708.0; p = 0.055, Wilcoxon rank sum test with conti-
uity correction) (Fig. 2). This indicates that in MDS  patients the
ower platelet count is related to the presence of PAIgG antibodies,
uggesting an immune component of thrombocytopenia in these
atients.
.4. Plasma glycocalicin index (GCI) is associated with the
mount of PAIgG measured by PIFT (R)In order to evaluate the platelet turnover, we calculated the GCI
f all patients. GC index was increased in patients with myelodys-
lastic syndrome overall (median, min–max: 1.82, 0.38–26.26) and
ig. 2. Correlation between PIFT (R) and thrombocytopenia. (A) A higher PIFT positivity wa
istributions of amount of PAIgG were signiﬁcantly higher in patents with platelet countr in patients with platelet counts below 100 × 109/L (A) and there is an inverse
markedly increased in patients with platelet counts <100 × 109/L
(median, min–max: 3.87, 1.44–26.26 p < 0.001, Wilcoxon rank sum
test). There was  also a positive correlation between GCI and PAIgG
(ﬂuorescence ratio) (p < 0.001, r = 0.36, Spearman’s rank correla-
tion rho), and the value of the GCI was signiﬁcantly higher in the
group of patients who presented a positive PIFT (median, min–max:
2.98, 0.50–26.26) compared to patients with a negative PIFT (1.33,
0.38–20.45) (p = 0.019, Wilcoxon rank sum test with continuity cor-
rection) (Fig. 3).
3.5. Hyper-destructive thrombocytopenia in worse prognosis
MDS  patients
Thrombocytopenia was associated with groups of worse prog-
nosis classiﬁed through IPSS (median, min–max: 180.0 ×109/L,
24.1–708.0 (low-risk); 84.0 × 109/L, 6.7–283.0 (intermediate-1
risk); 31.3 ×109/L, 18.5–95.4 (intermediate-2 risk); 31.0 × 109/L,
31.0–31.0 (high-risk); p = 0.0058, Kruskal–Wallis rank sum test).
Interestingly, the worse prognosis IPSS groups were also asso-
ciated with a higher positivity of PIFT (median, min–max: 1.21,
0.58–5.48 (low-risk); 1.33, 0.47–6.98 (intermediate-1 risk); 3.08,
2.84–27.88 (intermediate-2 risk); 11.2, 11.2–11.2 (high-risk);
p = 0.039, Kruskal–Wallis rank sum test), Fig. 4 indicating that an
important immune component may  contribute to produce lower
platelet counts in the advanced stages of the disease.4. Discussion
In this study, we have determined the presence of anti-
bodies adhered to platelet membrane through PIFT (platelet
s found in MDS  patients with platelet counts < 100 ×109/L. (B) Cumulative frequency
s <100 ×109/L.
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Fig. 3. Correlation between GC indices with platelet count and PIFT (R). CG index was signiﬁcantly higher in thrombocytopenic patients (A) and signiﬁcantly and directly
correlated with PIFT(R) (B).
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tig. 4. Platelet count, PIFT (R) and GCI according to IPSS. In worse prognosis disea
ount  (A), increase of PIFT (R) and GCI (B) and (C).
mmunoﬂuorescence test) assay, the impact of the presence of
hese antibodies in platelet counts and in plasma levels of glyco-
alicin, and we have established routine platelet indices, such as
PV  and PDW, which could indicate immune platelet destruction
n myelodysplastic syndromes.
Increased apoptosis of early progenitors and inhibitory effects of
ytokines are considered the main factors that contribute to throm-
ocytopenia in MDS. On the other hand, the link between immune
lterations and MDS  is already widely known, but the speciﬁc asso-
iation between thrombocytopenia and an immune component is
till poorly explored.
Determination of anti-platelet antibodies commonly requires
aborious and expensive techniques which are unavailable in most
ervices. Hence the use of easier and broadly available approaches
ould represent a breakthrough in the differential diagnosis and
nstitution of treatment for these patients. Our results demonstrate
hat a positive PIFT (R), and higher MPV  could discriminate those found an augmentation of platelet destruction conﬁrmed by decrease in platelet
patients with MDS  with a hyperdestructive component of thrombo-
cytopenia, which taken together with the previous data in literature
could suggest that higher MPV  and PDW in MDS  is associated with
an immune-mediated hyperdestructive thrombocytopenia [19].
Interestingly, despite the low number of patients in INT-2 and high
IPSS risk groups, we have also demonstrated a correlation between
direct PIFT and increasing IPSS score. This ﬁnding suggests that the
increase in direct PIFT could be an indicator of selective growth
advantage of the malignant clone, since progression in cytogenetic
abnormalities and exposure of new antigens sites could be related
to increase binding of IgG to platelets. The autoimmune attack on
bone marrow is triggered by abnormal antigens present in MDS
cells. CD8 T-cell responses against a number of leukemia-associated
antigens presented by myeloid cells have been demonstrated
in myeloid malignancy patients, including overexpressed self-
proteins such as hyaluronic acid which is the receptor-mediated
motility (RHAMM) [20], proteinase 3 (PR-1) [21], and Wilms tumor
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ntigen 1 (http://www.ncbi.nlm.nih.gov/gene/7490) [22], and also
eoantigens created by chromosomal translocations [23] would be
nvolved in this process. These autoimmune abnormalities could
eﬂect the presence of an incipient immune response against the
eukemic phenotype, though insufﬁcient to prevent its evolution
y deregulation of other interactions such as increased frequency
f Tregs and decreased function of NK cells [24].
Wang et al. demonstrated the presence of plasma speciﬁc
utoantibodies against platelet GP II b/III a and GP Ib/IX in
DS  patients using a modiﬁed monoclonal antibody speciﬁc
mmobilization platelet antigen assay (MAIPA), indicating a corre-
ation of patient thrombocytopenia with immune factors and that
utoantibody-mediated platelet destruction may  be involved in the
athogenesis of MDS  [25]. The use of a test by ﬂow cytometry
s PIFT would be easier to run and could suggest the pres-
nce of antibodies to platelets adhered with clinical signiﬁcance
n an initial screening of MDS  patients with thrombocytope-
ia.
Antiplatelet antibody assays, such as the monoclonal antibody-
peciﬁc immobilization of platelet antigens, are relatively speciﬁc
ut not very sensitive and appear to be only semiquantitative.
espite the speciﬁcity of PIFT, it will always remain lower than that
f MAIPA, therefore quantitative PIFT is not intended as a replace-
ent for GP-speciﬁc tests. However, in MDS  patients who present
ith thrombocytopenia, especially those requiring platelet trans-
usion, we recommend the quantitative PIFT as a highly sensitive
creening test, as suggested by other authors [26], since GP-speciﬁc
ntibodies have rarely been detected in cases where the PIFT was
egative.
Supporting our hypothesis of increased platelet destruction in
atients with MDS, Barsam et al. [27] recently described a higher
lycocalicin index in IPT patients.
An important application of our study is the possibility of
orticosteroid therapy in thrombocytopenic patients with MDS.
owever, immunosuppressive treatment may  fail because, in
ddition to the presence of antibodies against platelets, megakary-
poiesis failure exits and therefore only immunosuppressive
herapy is not enough. Some options to be taken into account are the
ssociations with agents that increase platelet count, stimulating
egakaryopoiesis and thereby increasing thrombopoiesis as the
se of thrombopoietin receptor agonists (TPO-A), which increases
lood levels of transforming growth factor- [28], activates the
AK/STAT and MAPK signaling pathways, and increases bone mar-
ow precursor proliferation and platelet production [29,30] or the
se of monoclonal antibody anti-Fc RIII that inhibits the destruction
f antibody-coated platelets [31].
The deﬁnition of an immune component in thrombocytope-
ia has been recently explored in myelodysplasia and, in practice,
he diagnosis of antibodies against plateles is extremely important
n this disease, since thrombocytopenia is supposedly related to
one marrow failure. Thus, the diagnosis of the immune compo-
ent avoids unnecessary transfusions in MDS  and could guide the
ppropriate treatment. The use of sophisticated methods as MAIPA
ssay often delays or even fails to diagnose the cause of immune
hrombocytopenia in this group of patients. We  believe that direct
IFT used as a sensitive screening test associated with the MPV  test
epresents an applicable and easy method to suggest the immune
estruction of platelets in patients with MDS, providing a diagnos-
ic change and changes in the conduct adopted in the treatment of
atients. Thus, we propose that the combination of a platelet index
MPV) and a highly sensitive and easy to perform screening test for
he detection of PAIgG (PIFT) could be applied to select a subset of
DS  patients in which we  would be able to prevent the overuse of
nnecessary platelet transfusions and who could be candidate for
n immunosuppressive therapeutic approach validated in clinical
tudies.
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